MitraClip Valve Repair for Mitral Valve Regurgitation
Beaumont was the first hospital in Metro Detroit to treat patients in a clinical study evaluating the MitraClip system to repair the mitral valve without heart surgery. The results of the clinical data that studied the MitraClip implant demonstrated safety, reduction of mitral valve regurgitation, rapid recovery, improvement in symptoms and reduction in hospitalizations for heart failure.
In October 2013, the FDA approved the use of the MitraClip to treat patients with degenerative mitral valve regurgitation. Beaumont was the first hospital in Michigan to implant the commercially approved MitraClip to help high-risk patients with degenerative mitral valve regurgitation. Surgery is typically not an option for these patients because of the severity of their condition.
Recent trial research demonstrated the success of MitraClip for patients diagnosed with moderate-to-severe or severe secondary mitral valve regurgitation and heart failure.
According to George Hanzel, M.D., Medical Director of Cardiac Catheterization Labs at Beaumont Hospital, Royal Oak explains, "The stunning results of the trial will fundamentally alter how we treat patients with significant mitral valve regurgitation and congestive heart failure. It is tremendous to have a therapy that reduces both heart failure hospitalizations and mortality in this group of patients."